Home › Companies › Amicus Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Amicus Therapeutics, Inc.’s Form 8-K, filed March 3, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of March 3, 2026: 2 items on Amicus Therapeutics, Inc.’s Form 8-K, filed March 3, 2026: 2 approved.
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Amicus Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Amicus Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed March 3, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. The Merger Proposal To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the " Merger Agreement "), dated December 19, 2025, by and among the Company, Parent, and Lynx Merger Sub 1, Inc., a Delaware corporation and wholly owned | 234,593,492 | 119,194 | 72,557 | -- | 0 | 99.9% | Approved | — |
| 2. The Compensation Proposal To approve, on a non-binding, advisory basis, the payment of certain compensation that may be paid or become payable to the Company's named executive officers that is based on or otherwise relates to the Merger | 209,150,012 | 24,282,220 | 1,353,011 | -- | 0 | 90% | Approved | — |
Source: Amicus Therapeutics, Inc., Form 8-K, filed with the SEC on March 3, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
294 asset managers disclosed a vote on at least one Amicus Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Amicus Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), dated December 19, 2025, by and among Amicus Therapeutics, Inc., a Delaware corporation ("Amicus"), BioMarin Pharmaceutical Inc., a Delaware corporation ("BioMarin"), and Lynx Merger Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of BioMarin ("Merger Sub"), pursuant to which Merger Sub will merge with and into Amicus (the "Merger"), and Amicus will become a direct or indirect wholly owned subsidiary of BioMarin.
Amicus Therapeutics, Inc.’s own tally for this item (“1. The Merger Proposal To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the " Merger Agreement "), dated December 19, 2025, by and among the Company, Parent, and Lynx Merger Sub 1, Inc.,”): 234,593,492 for, 119,194 against — passed, per its Form 8-K filed March 3, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 1: The Merger Proposal To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the " Merger Agreement "), dated December 19, 2025, by and among the Company, Parent, and Lynx Merger Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of Parent (" Merge…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 73 asset managers below reported 83,589,026 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 26,929,919 | 0 | 0 | 0 | For |
| BlackRock | 19,226,223 | 0 | 0 | 0 | For |
| State Street | 8,842,380 | 0 | 0 | 0 | For |
| Fidelity | 7,349,428 | 0 | 0 | 0 | For |
| TIAA | 4,370,668 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 3,407,986 | 0 | 0 | 0 | For |
| Charles Schwab | 2,571,839 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 1,835,830 | 0 | 0 | 0 | For |
| Invesco | 1,094,386 | 0 | 0 | 0 | For |
| Equitable | 684,998 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 589,400 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 578,897 | 0 | 0 | 0 | For |
| Investment Managers Series Trust II | 576,987 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 489,676 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 405,743 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 341,461 | 0 | 0 | 0 | For |
| ProShares | 278,921 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 271,899 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 261,258 | 0 | 0 | 0 | For |
| New York Life | 260,800 | 0 | 0 | 0 | For |
| Lincoln Financial | 242,124 | 0 | 0 | 0 | For |
| First Trust | 215,521 | 0 | 0 | 0 | For |
| Northern Trust | 186,173 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 177,676 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 162,836 | 0 | 0 | 0 | For |
Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).
100% of fund votes cast · no official result
The 2 asset managers below reported 294,749 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JPMorgan | 290,536 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 4,213 | 0 | 0 | 0 | For |
89% of fund votes cast · no official result
Description as filed by funds: To approve the adjournment of the special meeting, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of the adoption of the Merger Agreement at the time of the special meeting.
The 72 asset managers below reported 74,335,795 for, 9,228,379 against, 24,503 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 26,929,919 | 0 | 0 | 0 | For |
| BlackRock | 19,226,223 | 0 | 0 | 0 | For |
| State Street | 22,631 | 8,819,749 | 0 | 0 | Against |
| Fidelity | 7,349,428 | 0 | 0 | 0 | For |
| TIAA | 4,370,668 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 3,407,986 | 0 | 0 | 0 | For |
| Charles Schwab | 2,571,839 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 1,835,830 | 0 | 0 | 0 | For |
| Invesco | 1,094,386 | 0 | 0 | 0 | For |
| Equitable | 684,998 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 589,400 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 578,897 | 0 | 0 | 0 | For |
| Investment Managers Series Trust II | 576,987 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 489,676 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 405,743 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 341,461 | 0 | 0 | 0 | For |
| ProShares | 278,921 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 271,899 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 261,258 | 0 | 0 | 0 | For |
| New York Life | 260,800 | 0 | 0 | 0 | For |
| Lincoln Financial | 42,724 | 199,400 | 0 | 0 | Mixed |
| First Trust | 215,521 | 0 | 0 | 0 | For |
| Northern Trust | 186,173 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 177,676 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 162,836 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
100% of fund votes cast · no official result
The 2 asset managers below reported 294,749 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JPMorgan | 290,536 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 4,213 | 0 | 0 | 0 | For |
Combines 9 wordings of this item as funds reported it.
90% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the payment of certain compensation that may be paid or become payable to Amicus' named executive officers that is based on or otherwise relates to the Merger.
Amicus Therapeutics, Inc.’s own tally for this item (“2. The Compensation Proposal To approve, on a non-binding, advisory basis, the payment of certain compensation that may be paid or become payable to the Company's named executive officers that is based on or otherwise re”): 209,150,012 for, 24,282,220 against — passed, per its Form 8-K filed March 3, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The following advisory votes were cast at the Special Meeting (in person or by proxy) and the Compensation Proposal was approved:”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 26,929,894 | 25 | 0 | 0 | For |
| BlackRock | 19,226,223 | 0 | 0 | 0 | For |
| State Street | 8,834,208 | 8,172 | 0 | 0 | For |
| Fidelity | 7,349,428 | 0 | 0 | 0 | For |
| TIAA | 0 | 4,370,668 | 0 | 0 | Against |
| Delaware/Macquarie | 3,407,986 | 0 | 0 | 0 | For |
| Charles Schwab | 2,571,839 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 1,835,830 | 0 | 0 | 0 | For |
| Invesco | 1,094,386 | 0 | 0 | 0 | For |
| Equitable | 439,428 | 245,570 | 0 | 0 | Mixed |
| PRIMECAP Odyssey Funds | 589,400 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 578,897 | 0 | 0 | 0 | For |
| Investment Managers Series Trust II | 576,987 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 489,676 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 405,743 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 341,461 | 0 | 0 | 0 | For |
| ProShares | 278,921 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 271,899 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 261,258 | 0 | 0 | 0 | For |
| New York Life | 260,800 | 0 | 0 | 0 | For |
| Lincoln Financial | 199,400 | 42,724 | 0 | 0 | Mixed |
| First Trust | 215,521 | 0 | 0 | 0 | For |
| Northern Trust | 186,173 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 177,676 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 162,836 | 0 | 0 | 0 | For |
Fund voting reports, all 72 managers: 78,355,688 for, 5,208,486 against, 24,503 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 14,621,504 | 19,084 | 0 | 0 | For |
| Fidelity | 841,719 | 12,427,000 | 0 | 0 | Mixed |
| BlackRock | 12,411,021 | 0 | 0 | 0 | For |
| OAK RIDGE INVESTMENTS LLC | 9,335,173 | 0 | 0 | 0 | For |
| Pentwater Capital Management LP | 9,335,173 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 7,365,996 | 0 | 0 | 0 | For |
| GLAZER CAPITAL, LLC | 5,355,943 | 0 | 0 | 0 | For |
| Nuveen | 0 | 4,479,261 | 0 | 0 | Against |
| AQR | 4,017,992 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,400,248 | 463,716 | 0 | 0 | Mixed |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 3,833,710 | 0 | 0 | 0 | For |
| Citadel | 3,409,464 | 0 | 0 | 0 | For |
| Palo Alto Investors LP | 2,594,705 | 0 | 0 | 0 | For |
| Charles Schwab | 2,573,178 | 0 | 0 | 0 | For |
| Vanguard | 2,535,446 | 0 | 0 | 0 | For |
| TIG Advisors, LLC | 2,533,230 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 2,412,311 | 0 | 0 | Against |
| Northern Trust | 2,388,482 | 0 | 0 | 0 | For |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,272,031 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,000,000 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 1,850,772 | 0 | 0 | 0 | For |
| ALPINE ASSOCIATES MANAGEMENT INC. | 1,572,176 | 0 | 0 | 0 | For |
| Verition Fund Management LLC | 1,461,078 | 0 | 0 | 0 | For |
| Renaissance | 1,450,193 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,407,463 | 0 | 0 | 0 | For |
Institutional-manager reports, all 236 managers: 127,721,077 for, 21,448,035 against, 60,706 abstained. Showing the 25 largest; every one is in the interactive database (link above).
96% Fund and manager reports combined; may count the same shares twice · no official result
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JPMorgan | 0 | 290,536 | 0 | 0 | Against |
| CLEARWATER INVESTMENT TRUST | 0 | 4,213 | 0 | 0 | Against |
Fund voting reports, all 2 managers: 294,749 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| HBK INVESTMENTS L P | 6,186,958 | 0 | 0 | 0 | For |
| Varenne Capital Partners | 180,818 | 0 | 0 | 0 | For |
| Sarasin & Partners LLP | 0 | 600 | 0 | 0 | Against |
| Colony Family Offices, LLC | 48 | 0 | 0 | 0 | For |
Institutional-manager reports, all 4 managers: 6,367,824 for, 600 against.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported.
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | Vanguard | 26,929,919 |
| 2 | BlackRock | 19,226,223 |
| 3 | State Street | 8,842,380 |
| 4 | Fidelity | 7,349,428 |
| 5 | TIAA | 4,370,668 |
| 6 | Delaware/Macquarie | 3,407,986 |
| 7 | Charles Schwab | 2,571,839 |
| 8 | NEXPOINT FUNDS I | 1,835,830 |
| 9 | Invesco | 1,094,386 |
| 10 | Equitable | 684,998 |
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | State Street | 14,640,588 |
| 2 | Fidelity | 13,268,719 |
| 3 | BlackRock | 12,411,021 |
| 4 | OAK RIDGE INVESTMENTS LLC | 9,335,173 |
| 5 | Pentwater Capital Management LP | 9,335,173 |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 7,365,996 |
| 7 | GLAZER CAPITAL, LLC | 5,355,943 |
| 8 | Nuveen | 4,479,261 |
| 9 | AQR | 4,017,992 |
| 10 | Goldman Sachs | 3,863,964 |
Shown as share counts, not percentages: no shares-outstanding figure has been matched to Amicus Therapeutics, Inc. for the 2025-2026 season, so there is no denominator to divide by.
At Amicus Therapeutics, Inc.'s shareholder meeting held March 3, 2026, in the 2025-2026 proxy season, 294 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 937 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the payment of certain compensation that may be… — Amicus Therapeutics, Inc.'s filing reports the proposal as approved, with 90% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Amicus Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on March 3, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Amicus Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Amicus Therapeutics, Inc. 2026 Special Meeting: Vote Results”, https://proxyvotesnow.com/company/amicus-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.